Noradrenaline Kabi (Noradrenaline Tartrate)

Noradrenaline tartrate acts as an agonist at α1‑adrenergic receptors, causing vasoconstriction that raises systemic vascular resistance and arterial pressure. It also stimulates β1‑adrenergic receptors in the heart, enhancing contractility and cardiac output, thereby stabilising haemodynamics during shock states.

The dose of Noradrenaline Kabi is individualized and set by the treating physician based on the patient’s haemodynamic status, target blood pressure, and response to therapy. Dosing is typically administered as a continuous intravenous infusion that is titrated to achieve the desired mean arterial pressure.

Safety data for Noradrenaline Kabi in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Noradrenaline Kabi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Noradrenaline Kabi is often preferred over dopamine because it provides more predictable α‑adrenergic vasoconstriction with less tachyarrhythmia. Compared with epinephrine, it has a stronger α‑effect and a weaker β‑effect, making it useful when raising blood pressure is the primary goal while minimizing excessive heart rate increase.

Noradrenaline Kabi must be stored at 2‑8 °C in a refrigerator, protected from light. The product should not be frozen or shaken. During transport, maintain the cold‑chain conditions and keep the vial in its original packaging to preserve stability.

Noradrenaline Kabi is administered intravenously, usually via a calibrated infusion pump. The drug is diluted in a compatible carrier solution and infused continuously, with the rate adjusted according to the patient’s blood pressure response and clinical goals.

Serious risks include severe hypertension, myocardial ischemia, and tissue necrosis at the infusion site due to intense vasoconstriction. Clinicians should monitor cardiac rhythm, arterial pressure, and peripheral perfusion closely, and be prepared to adjust or discontinue therapy if these complications arise.

Noradrenaline Kabi is contraindicated in patients with known hypersensitivity to noradrenaline or any of its excipients, and it should be avoided in individuals with uncontrolled severe hypertension or peripheral vascular disease where further vasoconstriction could cause critical limb ischemia.